文献速递临床试验与 GCP

短波透热治疗新型冠状病毒肺炎疗效的随机对照试验方案结构化摘要

The curative effects of shortwave diathermy on treating Novel coronavirus (COVID-19) pneumonia: A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-07-03

该研究为单中心、评估者盲法、平行组、优效性随机对照试验,计划纳入410例COVID-19肺炎患者,按1:1随机分为标准治疗联合超短波透热治疗组和单纯标准治疗组,主要结局为咽拭子核酸检测转阴时间,旨在评估超短波透热的疗效。

要点

  • 超短波透热治疗每次10分钟,每日两次,连续12天,联合标准治疗。
  • 主要结局指标为第7、14、21、28天评估的咽拭子核酸转阴时间。
  • 计划纳入410例,实验组和对照组各205例,评估者盲法。

核心结论

  • 该研究旨在评估超短波透热治疗对COVID-19肺炎的治疗效果,假设其可减轻肺部炎症并缩短核酸转阴时间。

研究设计与样本

  • 单中心、2臂(1:1比例)、评估者盲法、平行组、优效性随机对照临床试验,计划纳入410例患者,实验组和对照组各205例。
  • 纳入标准为年龄18-65岁、COVID-19核酸检测阳性、肺部CT显示多发斑片状磨玻璃影或双肺其他典型表现。
  • 排除标准包括需ICU管理、其他病原体阳性、呼吸衰竭或需机械通气、金属植入物或起搏器、休克、出血倾向或活动性出血、多器官衰竭、癌症或严重基础疾病、妊娠或哺乳期、严重认知障碍、未签署知情同意书及短波其他禁忌症。
  • 随机化采用在线www.randomization.com生成的置换区组法,由不参与研究的统计学家完成,使用不同大小的区组。
  • 由于干预性质,患者和医护人员无法设盲,仅评估者设盲。

关键数值与推荐

  • 实验组接受国家推荐标准治疗+超短波透热治疗,电极置于躯干前后部,每次10分钟,每日两次,连续12天。
  • 对照组仅接受国家推荐标准治疗,不接受超短波治疗。
  • 主要结局指标为咽拭子核酸检测转阴时间(天),在第7、14、21、28天评估。
  • 次要结局指标包括核酸检测率、症状恢复、生命体征评估、CT、全血细胞计数、血清分析和SIRS量表评分。
  • 盲法评估在基线(开始超短波透热治疗当天)和干预后28天进行。

局限性

  • 患者和医护人员无法设盲,仅评估者盲法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the therapeutic effects of ultra-short-wave diathermy (SWD) on COVID-19 pneumonia. The hypothesis is that SWD may minimise pneumonic inflammation and shorten the duration of the time to positive-to-negative conversion of COVID-19 nucleic acid test. TRIAL DESIGN: This is a single centre, 2-arm (1:1 ratio), evaluator blinded, parallel group design superiority randomised, controlled clinical trial. PARTICIPANTS: The inclusion criteria were: (1) Age 18-65 years, (2) COVID-19 nucleic acid test is positive, (3) Lung CT showed multiple patchy ground glass shadows or other typical manifestations of both lungs. The exclusion criteria were: (1) Patients who need ICU management, (2) Positive tests for other pathogens such as Tuberculosis, Mycoplasma, (3) Patients with respiratory failure or requiring mechanical ventilation, (4) Patients with metal implants or pacemakers, (5) Those with shock (6) Those that have bleeding tendency or active bleeding in the lungs, (7) Patients with multiple organ failure who need ICU monitoring and treatment, (8) Cancer patients and those with severe underlying diseases, (9) Pregnant or lactating women, (10) Patients with severe cognitive impairment who cannot follow the instructions to complete the treatment, (11) Those without signed informed consent and (12) Those with other contraindications to short wave. This study will be conducted in Tongji Hospital, Caidian, Wuhan, People's Republic of China. INTERVENTION AND COMPARATOR: The experimental group will be given the nationally recommended standard medical treatment + ultra-short-wave diathermy treatment. Ultra-short-wave therapy treatment will be performed through application of ultra-short-wave therapy machine electrodes on the anterior and posterior parts of the trunk for 10 minutes, twice a day for 12 consecutive days. The comparator will be the control, not receiving ultra-short-wave therapy, and will be given only the nationally recommended standard medical treatment. MAIN OUTCOMES: The primary outcome measures will be time to positive-to-negative conversion of COVID-19 nucleic acid test by pharyngeal swab, in days assessed at 7th, 14th ,21st and 28th days. The secondary outcome measures include nucleic acid test rate and recovery from symptoms, Vital signs assessment, Computed Tomography, Complete blood count, serum analysis and SIRS scale scores. Blinded evaluation will be at baseline (the day of starting ultra-short-wave diathermy) and after 28 days following the interventions. RANDOMISATION: A Randomization plan will be generated online on www.randomization.com using permuted blocks method, by a statistician who will not be part of the study. Small blocks of various sizes will be used. Patients will be randomized (1:1) between the experimental and control groups BLINDING (MASKING): This will be an evaluator blinded study. Due to the nature of the intervention, blinding of patients and healthcare workers is not possible. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 410 patients will be randomised in 1:1 ratio to two groups: experimental group (n=205) and control group (n=205). TRIAL STATUS: Protocol version 1 was approved on 02/12/2020. Recruitment for this trial began on 02/18/2020 and will be ongoing till the required sample size is reached. The analysis deadline is August 2020. TRIAL REGISTRATION: This randomised controlled trial has been prospectively registered with the Chinese Clinical Trials ( ChiCTR2000029972 ) on 17 February 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol." The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nasb M, Sayed Shah ZA, Huang L, et al. The curative effects of shortwave diathermy on treating Novel coronavirus (COVID-19) pneumonia: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 32620144. doi:10.1186/s13063-020-04534-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。